What's Next In Biopharma And CGT?

The biopharmaceutical landscape is undergoing a fundamental shift toward single-use technologies across emerging therapeutic modalities, including specialized cell therapies, gene therapies, and mRNA. Accelerating facility construction timelines and mitigating capital exposure remain primary drivers behind replacing traditional stainless steel systems. However, ongoing industry evolution introduces operational complexity, requiring robust standardization around material qualification, biocompatibility testing, and extractables risk management. As guidance updates like USP 665 take effect, cross-industry collaboration through consensus standards bodies and trade groups is vital to establish reliable testing baselines without suppressing technical innovation. Navigating these regulatory shifts requires aligning supply chain controls, in vitro testing methodologies, and lifecycle qualification protocols. Listen to the full podcast conversation to explore historical bioprocess milestones, emerging standardization frameworks, and practical strategies for optimizing modern single-use manufacturing operations across complex pipeline modalities.